These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28988277)

  • 41. Primary Rod and Cone Degeneration Is Prevented by HDAC Inhibition.
    Trifunović D; Petridou E; Comitato A; Marigo V; Ueffing M; Paquet-Durand F
    Adv Exp Med Biol; 2018; 1074():367-373. PubMed ID: 29721965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
    Suresh PS; Devaraj VC; Srinivas NR; Mullangi R
    Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27511598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
    Watanabe T; Kato H; Kobayashi Y; Yamasaki S; Morita-Hoshi Y; Yokoyama H; Morishima Y; Ricker JL; Otsuki T; Miyagi-Maesima A; Matsuno Y; Tobinai K
    Cancer Sci; 2010 Jan; 101(1):196-200. PubMed ID: 19817748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel.
    Zhu J; Zhao Y; Wang L; Zhou C; Zhou S; Chen T; Chen J; Zhang Z; Zhu Y; Ding S; Shao F
    Eur J Pharm Sci; 2021 Dec; 167():106006. PubMed ID: 34520836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
    Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
    Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
    Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
    Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
    de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
    Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
    Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
    Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
    Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
    Jasek E; Gajda M; Lis GJ; Jasińska M; Litwin JA
    Anticancer Res; 2014 Apr; 34(4):1849-56. PubMed ID: 24692719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.
    Chidambaran V; Venkatasubramanian R; Sadhasivam S; Esslinger H; Cox S; Diepstraten J; Fukuda T; Inge T; Knibbe CAJ; Vinks AA
    Paediatr Anaesth; 2015 Sep; 25(9):911-923. PubMed ID: 25975390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
    Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
    Tylutki Z; Mendyk A; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.